title: Association between anatomopathologic graft disorders during reperfusion and vena cava sIL-2r in orthotopic liver transplantation.
abstract: Graft ischemia-reperfusion injury during orthotopic liver transplantation (OLT) is associated with anatomic and pathologic disorders in the graft, which may cause initial dysfunction. The object of this paper was to evaluate sIL-2r as an indicator of liver damage during graft reperfusion.
  
  
  METHODS
  Blood samples were drawn from 20 consecutive patients who required OLT secondary to chronic end-stage insufficiency various sites (portal vein, vena cava, pulmonary artery) and during different surgical phases. Following centrifugation and storage at -70 degrees C, sIL-2r was quantitated by chemiluminescence (Immulite, EURO/DPC). In addition biopsies were graded from 0 to III according to the anatomic and pathologic findings. Base excess and ammonia were measured to evaluate the function of the new liver.
  
  
  METHODS
  Parameter associations were explored using Spearman's Rho and Kendall's Tau-b methods.
  
  
  RESULTS
  There was a correlation between the degree of graft preservation and sIL-2R both during vena cava reperfusion (r=.0591, P=.05) and for the initial 2 hours after reperfusion (r=0.61, P=.062).
  
  
  CONCLUSIONS
  sIL-2r levels drawn from the vena cava after graft reperfusion are associated with its degree of injury.
authors.affiliation: Liver Transplant Unit, Research Unit, University Hospital Clinic (Barcelona), University Hospital NS de Candelaria, Tenerife, Spain. javierar@teleline.es
authors.forename: J
authors.initials: J
authors.lastname: Arranz
authors.forename: A
authors.initials: A
authors.lastname: Soriano
authors.forename: I
authors.initials: I
authors.lastname: Garcia
authors.forename: I
authors.initials: I
authors.lastname: Garcia
authors.forename: M T
authors.initials: MT
authors.lastname: Concepción
authors.forename: J
authors.initials: J
authors.lastname: Navarro
authors.forename: A
authors.initials: A
authors.lastname: Arteaga
authors.forename: X
authors.initials: X
authors.lastname: Filella
authors.forename: F
authors.initials: F
authors.lastname: Gonzalez
authors.forename: C
authors.initials: C
authors.lastname: Fernández
authors.forename: M
authors.initials: M
authors.lastname: Barrera
authors.forename: L
authors.initials: L
authors.lastname: Muñoz
authors.forename: A J
authors.initials: AJ
authors.lastname: Perera
authors.forename: J L
authors.initials: JL
authors.lastname: Pozo
authors.forename: A
authors.initials: A
authors.lastname: Jiménez
authors.forename: M
authors.initials: M
authors.lastname: Macia
authors.forename: I
authors.initials: I
authors.lastname: Arteaga
mesh_terms: D004359:Drug Therapy, Combination; D006498:Hepatectomy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007773:Lactates / Q000097:blood; D017093:Liver Failure / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000379:methods / Q000473:pathology*; D015375:Receptors, Interleukin-2 / Q000097:blood*; D015424:Reperfusion; D014508:Urea / Q000097:blood; D014684:Venae Cavae
chemical_list: D007166:Immunosuppressive Agents; D007773:Lactates; D015375:Receptors, Interleukin-2; D014508:Urea